|
|
|||||||||
Clinical Investigations |
1 Department of Clinical Radiology, University of Kuopio and Kuopio University Hospital, Kuopio, Finland
2 Department of Clinical Physiology and Nuclear Medicine, University of Kuopio and Kuopio University Hospital, Kuopio, Finland
3 Department of Radiology, Helsinki University Central Hospital, Helsinki, Finland
4 Department of Medicine, University of Kuopio and Kuopio University Hospital, Kuopio, Finland
5 Niuvanniemi Hospital, Kuopio, Finland
Hypertrophic cardiomyopathy (HCM) is a genetic disease caused by mutations in genes encoding sarcomeric proteins. However, other genetic and possibly also environmental factors modify the phenotypic expression of left ventricular (LV) hypertrophy. The present study investigated whether cardiac adrenergic activity affects the severity of LV hypertrophy in genetically identical patients with HCM. Methods: The study population consisted of 21 patients with HCM caused by the Asp175Asn substitution of the
-tropomyosin gene (TPM1-Asp175Asn) and 9 healthy volunteers. LV mass and segmental wall thickness were measured with MRI. Presynaptic cardiac adrenergic activity was measured with 123I-metaiodobenzylguanidine (MIBG) SPECT. Global and segmental washouts of 123I-MIBG were calculated. Results: Global myocardial 123I-MIBG washout was faster in patients with TPM1-Asp175Asn than in healthy volunteers (50% ± 9% vs. 37% ± 8%, P = 0.001). In linear regression analysis, global 123I-MIBG washout was associated with the LV mass index and LV maximal wall thickness index in HCM patients (r = 0.512, P = 0.018, and r = 0.478, P = 0.028, respectively). The mean 123I-MIBG washout was higher in LV segments
15 mm thick than in LV segments < 15 mm thick (56 ± 10 vs. 49% ± 10%, P = 0.002). Conclusion: In patients with HCM sharing the same causal gene defect, the degree of LV hypertrophy is related to 123I-MIBG washout, suggesting that cardiac adrenergic activity modifies phenotypic expression in HCM.
Key Words: cardiomyopathy genetics hypertrophy MRI norepinephrine scintigraphy
This article has been cited by other articles:
![]() |
P. Sipola, K. Lauerma, P. Jaaskelainen, M. Laakso, K. Peuhkurinen, H. Manninen, H. J. Aronen, and J. Kuusisto Cine MR Imaging of Myocardial Contractile Impairment in Patients with Hypertrophic Cardiomyopathy Attributable to Asp175Asn Mutation in the {alpha}-Tropomyosin Gene Radiology, September 1, 2005; 236(3): 815 - 824. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Amano, S. Kumita, M. Takayama, and T. Kumazaki Comparison of Contrast-Enhanced MRI with Iodine-123 BMIPP for Detection of Myocardial Damage in Hypertrophic Cardiomyopathy Am. J. Roentgenol., August 1, 2005; 185(2): 312 - 318. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Isobe, H. Izawa, M. Iwase, M. Nanasato, M. Nonokawa, A. Ando, S. Ohshima, K. Nagata, K. Kato, T. Nishizawa, et al. Cardiac 123I-MIBG Reflects Left Ventricular Functional Reserve in Patients with Nonobstructive Hypertrophic Cardiomyopathy J. Nucl. Med., June 1, 2005; 46(6): 909 - 916. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |